Wall Street analysts forecast that Evogene Ltd (NYSE:EVGN) will announce earnings of ($0.13) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Evogene’s earnings. Evogene posted earnings of ($0.18) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 27.8%. The firm is expected to announce its next earnings report on Thursday, August 10th.

On average, analysts expect that Evogene will report full-year earnings of ($0.68) per share for the current fiscal year. For the next financial year, analysts expect that the company will report earnings of ($0.02) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Evogene.

Evogene (NYSE:EVGN) last issued its earnings results on Wednesday, May 17th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.18) by $0.01. Evogene had a negative net margin of 235.47% and a negative return on equity of 18.60%. The firm had revenue of $0.72 million during the quarter.

Shares of Evogene (NYSE:EVGN) traded up 11.98% on Tuesday, reaching $5.49. 97,893 shares of the company were exchanged. The firm’s market capitalization is $140.69 million. Evogene has a 12-month low of $4.65 and a 12-month high of $7.09. The company’s 50 day moving average is $5.15 and its 200 day moving average is $5.19.

Several hedge funds have recently bought and sold shares of EVGN. Goldman Sachs Group Inc. raised its stake in Evogene by 59.6% in the first quarter. Goldman Sachs Group Inc. now owns 606,962 shares of the biotechnology company’s stock valued at $3,246,000 after buying an additional 226,778 shares during the period. UBS Group AG raised its stake in Evogene by 10.1% in the first quarter. UBS Group AG now owns 1,052,537 shares of the biotechnology company’s stock valued at $5,628,000 after buying an additional 96,527 shares during the period. JPMorgan Chase & Co. raised its stake in Evogene by 53.4% in the first quarter. JPMorgan Chase & Co. now owns 245,425 shares of the biotechnology company’s stock valued at $4,079,000 after buying an additional 85,425 shares during the period. Bank of America Corp DE raised its stake in Evogene by 5.3% in the first quarter. Bank of America Corp DE now owns 841,552 shares of the biotechnology company’s stock valued at $4,500,000 after buying an additional 42,532 shares during the period. Finally, Jane Street Group LLC raised its stake in Evogene by 71.1% in the first quarter. Jane Street Group LLC now owns 50,129 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 20,837 shares during the period. 29.88% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/11/evogene-ltd-evgn-expected-to-post-earnings-of-0-13-per-share.html.

About Evogene

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.

Get a free copy of the Zacks research report on Evogene (EVGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evogene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.